MetLife (MET) Q2 2026 Earnings Preview

Reports: Wednesday, August 5, 2026 (after market close/pre-call Aug 6 timing per calendar); Earnings call for 2026Q2

1. Setup: A Stock at All-Time Highs Heading Into Print

MET shares have had a remarkable run into this print — climbing from roughly $71 in early April to an all-time closing high near $97 on July 28, before settling around $96 in the days before earnings. That's a ~35% advance in four months, comfortably outpacing the broader market and financial sector. The rally has been fueled by a blowout Q1 report, four consecutive sell-side price-target hikes in July (JPMorgan to $106, TD Cowen to $105, KBW to $105, Jefferies to $103), and confidence in management's "New Frontier" strategic execution — though one notable downgrade-in-target came from BofA (cut to $103 from $106). Consensus sits at a Buy/Moderate Buy rating with price targets clustering in the $90s–$100s.

That backdrop raises the bar: expectations are high, and the stock is priced for continued execution. Any wobble — even a well-explained one — could trigger profit-taking after such a strong run.

2. What Wall Street Expects

3. The Big Swing Factor: Variable Investment Income Guided Down Sharply

This is the single most important known data point going into the print. On June 29, MetLife pre-announced via 8-K that it expects Q2 variable investment income (VII) of only $220–270 million pre-tax — compared with $518 million in Q1 (which was itself a beat, near the top of guidance, driven by strong private-equity and venture-capital returns) and against full-year guidance of ~$1.6 billion.

Management flagged this on the Q1 call and again at Morgan Stanley's June financials conference: CFO John McCallion said the company "could see a little more pressure going into Q2" given how Q1 closed, but sounded more optimistic about Q3, pointing to a stronger market/IPO backdrop and MetLife's venture-capital exposure skewed toward AI names. Practically, this means: - Total company adjusted earnings growth in Q2 will likely decelerate meaningfully from Q1's 18% pace, purely on a VII comp/base-rate basis — this should not be read as an operating deterioration. - RIS spreads (which get a VII boost) may land toward the lower end of the 100–120bps guided range, even as the core (ex-VII) spread — which came in at 95bps in Q1 — is expected to be roughly flat to modestly better. - Asia and Corporate & Other, which together hold most of the company's VII-sensitive assets, will see the biggest earnings-growth optics hit.

Investors should be prepared for a headline adjusted-earnings/EPS growth rate well below Q1's, and the call will likely spend real time separating "VII noise" from underlying momentum.

4. Q1 Recap: The Bar-Setter

Q1 2026 was described by CEO Michel Khalaf as an "excellent quarter" and provides the framework analysts will use to judge Q2's underlying trends: - Adjusted EPS $2.42, +23% YoY; adjusted earnings $1.6B, +18% - Adjusted ROE 17.0%, at the top of the 15–17% New Frontier target range - Direct expense ratio 11.9%, better than the 12.1% full-year target — notable given it absorbed PineBridge's higher cost structure - Broad-based growth: every segment posted higher adjusted earnings (Group Benefits +19%, RIS +11%, Asia +31%, LatAm +5%, EMEA +33%, MIM +68%) - $1.1B returned to shareholders (buybacks + dividends) in Q1, plus another ~$200M of buybacks in April; dividend raised 4.4%

5. Segment Watch List for Q2

6. Capital, Balance Sheet & Litigation

7. Key Questions for Management

  1. How much of the Q2 earnings growth deceleration is purely VII timing versus any softening in core spreads, underwriting, or expense trends?
  2. Is the Group Benefits mortality/underwriting favorability durable, or will pricing competition erode it over coming quarters (management has said any pricing response would play out over years, not quarters)?
  3. Does RIS core spread inflect higher now that Q4's large PRT-driven asset rotation is further behind, or does a persistently flat yield curve keep spreads range-bound near 95bps?
  4. What's the state of MIM/PineBridge net flows — has the pipeline converted into actual net inflows yet?
  5. Any incremental disclosure on the Japan FSA secondment review, or update on the Sun Life indemnification dispute?
  6. Is full-year 2026 guidance (VII ~$1.6B, expense ratio ~12.1%, ROE 15–17%, buybacks in line with 2025) still intact given the Q2 VII shortfall?

8. Bottom Line

MetLife heads into Q2 earnings with the stock near all-time highs, a strong beat-and-raise track record, and broad sell-side support — but also with a known, pre-announced headwind in variable investment income that will make the headline year-over-year growth rate look much softer than Q1's 23% EPS surge. The real test for the print is whether underlying, VII-adjusted fundamentals — Group Benefits margins, RIS core spreads, Asia/LatAm volume growth, EMEA durability, and MIM integration progress — stay on track with the New Frontier targets (double-digit EPS growth, 15–17% ROE, declining expense ratio, 65–75% free cash flow conversion). Given how much good news is already priced into the stock after a ~35% four-month rally, the market's reaction is likely to hinge less on the VII-driven EPS number itself and more on management's tone regarding second-half spread trends, Group Benefits margin durability, and any fresh color on Japan regulatory or Sun Life litigation matters.